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Abstract
Background: In the investigation of autism spectrum disorders (ASD), a genetic cause is found in approximately 10–20%.
Among these cases, the prevalence of the rare inherited metabolic disorders (IMD) is unknown and poorly evaluated. An
IMD responsible for ASD is usually identified by the associated clinical phenotype such as dysmorphic features, ataxia,
microcephaly, epilepsy, and severe intellectual disability (ID). In rare cases, however, ASD may be considered as
nonsyndromic at the onset of a related IMD.
Objectives: To evaluate the utility of routine metabolic investigations in nonsyndromic ASD.
Patients and Methods: We retrospectively analyzed the results of a metabolic workup (urinary mucopolysaccharides,
urinary purines and pyrimidines, urinary creatine and guanidinoacetate, urinary organic acids, plasma and urinary amino
acids) routinely performed in 274 nonsyndromic ASD children.
Results: The metabolic parameters were in the normal range for all but 2 patients: one with unspecific creatine urinary
excretion and the other with persistent 3-methylglutaconic aciduria.
Conclusions: These data provide the largest ever reported cohort of ASD patients for whom a systematic metabolic workup
has been performed; they suggest that such a routine metabolic screening does not contribute to the causative diagnosis of
nonsyndromic ASD. They also emphasize that the prevalence of screened IMD in nonsyndromic ASD is probably not higher
than in the general population (,0.5%). A careful clinical evaluation is probably more reasonable and of better medical
practice than a costly systematic workup.
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Introduction
Autism spectrum disorders (ASD) are neurodevelopmental
disabilities characterized by an onset before three years of age, a
severe and pervasive impairment in reciprocal socialization,
qualitative impairment in communication, restricted interests
and repetitive behaviors [1]. The pathophysiology of ASD is
complex, highly genetic and multifactorial [2]. Currently, genetic
causes (chromosomal abnormalities or genetic alterations) of ASD
can be identified in about 10–20% of cases [3]. Among these, the
contribution of the rare inherited metabolic disorders (IMD)
remains poorly evaluated. ASD are frequently reported in IMD
with neuro-psychiatric involvement. In these situations, the IMD
responsible for ASD is usually identified by associated clinical signs
such as dysmorphic features, ataxia, microcephaly, epilepsy, and
intellectual disability (ID) [4,5]. In rare situations, however, ASD
may appear as an isolated disorder at the onset of a few IMDs (e.g.
mainly untreated phenylketonuria, classical homocystinuria,
Sanfilippo disease). The latter are important to identify as early
as possible since some of them are amenable to treatment. In many
child and adolescent psychiatry units, a metabolic screening is
routinely performed in all ASD patients whatever the associated
clinical phenotype. Specifically, in ASD patients considered as
nonsyndromic, i.e. those with no additional clinical symptoms
suggesting an IMD, the outcome of this practice has not been
evaluated. The aim of the present study was thus to retrospectively
explore the benefits of such a systematic screening in 274 ASD
patients considered as nonsyndromic.
Materials and Methods
Study design and population
A retrospective cohort study was conducted, and all children
included aged two to seventeen years, were hospitalized at the
Robert Debre ´ University Hospital (Paris, France), in two
specialized units labelled as reference centers for autism by the
French Health Ministry, and registered with a final diagnosis of
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enrolled in the study, patients were to be evaluated during three to
seven days by a multidisciplinary team including child psychia-
trists, child neurologists, geneticists, psychologists and speech
therapists. Diagnosis of ASD was based on DSM-IV criteria (APA,
1994) and strong clinical consensus among experts at the end of
the hospitalization. Patients already diagnosed with medical
disorders, identifiable neurological syndromes or focal neurolog-
ical signs were excluded (n=66). All patients with abnormal
genetic exams (high-resolution karyotyping, Fragile X syndrome,
15q11-q13, 22q11 and 22q13 deletions detected by fluorescence in
situ hybridization) performed during the hospitalization were
excluded (n=9). Patients with insufficient available information to
classify them as nonsyndromic were also excluded (n=39).
Associated ID was assessed with the Wechsler Intelligence Scale
for Children - third or fourth edition or the Wechsler Preschool
and Primary Scale of Intelligence. For patients with moderate to
profound ID or those who were non verbal, the cognitive level was
estimated with the Psycho-Educational-Profile Revised (PEP-R) or
the Brunet-Lezine developmental test [6]. Depending on the
results of these tests, patients were classified as high functioning
ASD patients (intellectual quotient or developmental quotient
above 70) or low functioning ASD patients.
Metabolic parameters
The following tests were performed: urinary mucopolysaccha-
rides (total glycosaminoglycan- DMB assay and electrophoresis),
urinary purines and pyrimidines (liquid chromatography-diode
array detector), urinary creatine and guanidinoacetate (tandem
mass spectrometry), urinary organic acids (gas chromatography-
mass spectrometry), plasma and urinary amino acids (liquid
chromatography-ninhydrine), respectively screening for muco-
polysaccharidoses, inborn errors of purine and pyrimidine
metabolism, creatine deficiency syndromes, organic acidurias
and aminoacidopathies.
SLC6A8 sequencing and creatine uptake assay
Mutation screening of SLC6A8 and creatine uptake assays in
cultured skin fibroblasts were performed as already reported [7,8].
Creatine uptake was measured after incubation with 25 mM
creatine. The measured intracellular creatine concentration was
expressed in picomol creatine per microgram total protein. The
incubations were performed in triplicate.
Ethics
The ethics committee of Robert Debre ´ University Hospital
(APHP, 75019 Paris, France) reviewed and approved the study.
For molecular exams, informed consent was obtained from
probands (if possible) and parents. However, the parents of
children did not provide explicit informed consent concerning the
metabolic exams, because the French ethical legislation specifies
that informed consent is automatically waived for retrospective
studies using patient files. Thus, the ethics committee of Robert
Debre ´ University Hospital (APHP, 75019 Paris, France) specifi-
cally waived the need for consent concerning these metabolic
exams.
Results
Among the 274 ASD patients enrolled in the study (Table 1),
only two patients showed persistent alterations in metabolic
parameters (Table 2): one with a 3-methylglutaconic aciduria and
the other with an elevated creatine urinary excretion (between 1.5
and 2 fold control values on 3 different measurements performed
on a 2-year period). Both patients exhibited autism, the first with a
moderate ID and the second one with a non verbal IQ in the
normal range. For the second patient, guanidinoacetate level was
normal both in plasma and urine as was plasma creatine level
(data not shown). To check for a creatine transport defect, SLC6A8
was sequenced from genomic DNA extracted from fibroblasts and
creatine uptake was assayed in fibroblasts. These two analyses
revealed no abnormalities, indicating no primary deficit in creatine
transport.
Discussion
Among the 274 patients with ASD considered as nonsyndromic,
we were unable to detect any patients with mucopolysaccharido-
ses, abnormalities of purine and pyrimidine metabolism, creatine
deficiency syndromes or aminoacidopathies. The only abnormal-
ities found were a non-specific increase in urinary creatine
excretion and a 3-methylglutaconic aciduria. These results suggest
that the prevalence of screened IMD in association with ASD is
low (,0.5%) and thus indicate the weak cost effectiveness of a
systematic metabolic workup in ASD considered as nonsyndromic.
Very few IMDs may begin with isolated ASD as a prominent
feature. For example, phenylketonuria (PKU) concerns the rare
neonates born in developed countries who escaped from neonatal
screening or the unscreened neonates born in countries for which
Table 1. Demographic and clinical characteristics of the
patients enrolled in the study.
Patients
n=274 %
Gender (male/female) 241/33 88/12
Mean age (6 SD) 7.363.6
ASD diagnosis
Autism 182 66
Asperger syndrome 18 7
PDD-nos 74 27
Associated ID 139 51
Mild to moderate ID 92 34
Severe to profound ID 47 17
ID: intellectual disability; PDD-nos: Pervasive Developmental Disorder - Not
Otherwise Specified.
doi:10.1371/journal.pone.0021932.t001
Table 2. Metabolic tests performed in the study.
Number of
subjects screened
for each test
Number (%) of
subjects with
abnormal test
Urinary mucopolysaccharides 236 0
Urinary purines and pyrimidines 238 0
Urinary creatine and
guanidinoacetate
203 1 (0.5)
Urinary organic acids 247 1 (0.4)
Urinary amino acids 247 0
Plasma amino acids 267 0
doi:10.1371/journal.pone.0021932.t002
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an isolated ASD over months or years that is usually secondarily
associated with behavioral disorders, epilepsy and severe ID
[9,10]. Similarly, children with classical homocystinuria (HCY)
due to cystathionine-b-synthase deficiency may exhibit isolated
autism [11]. The clinical picture may later be enriched by the
cardinal manifestations of HCY i.e. lens subluxation, vascular
thrombosis and skeletal abnormalities [12]. Isolated ASD may also
be observed at the onset of mucopolysaccharidosis type III (MPS
III) or Sanfilippo disease [13,14]. MPS III patients often present
with severe behavioral disorders and subtle signs of slowly
progressing cognitive impairment, primary including speech
regression and loss of toilet training and further leading to a
severe encephalopathy [15]. In addition, rare cases of urea cycle
disorders, especially ornithine transcarbamylase deficiency have
been reported in patients with nonsyndromic ASD [16]. In this
case, ASD are usually part of recurrent bouts of neuro-psychiatric
problems (behavioral disorders, ataxic gait) frequently associated
with hepato-digestive abnormalities [17]. These rare IMDs for
which ASD is an initial sign could justify a systematic minimal
metabolic screening in ASD patients considered as nonsyndromic,
especially because PKU, HCY and urea cycle disorders are
treatable conditions for which early recognition and treatment are
essential. Plasma amino acids (PKU, HCY, and urea cycle
disorders), post prandial plasma ammonia level (urea cycle
disorders) and urinary MPS profile (Sanfilippo disease) could be
proposed. In these disorders, however, the clinical picture
comprises with time additional signs such as severe behavioral
disorders, cognitive regression, ocular, liver or other neurological
signs. Careful reappraisal of the clinical signs is therefore
warranted and crucial because sometimes the initial diagnosis of
nonsyndromic ASD should be reconsidered in the presence of
subtle symptoms. At the Robert Debre ´ hospital, due to published
yet controversial recommendations [18,19], a systematic metabolic
workup is performed in all patients with ASD, whatever the
associated symptoms. These metabolic tests are not exhaustive and
concern various diseases with syndromic and nonsyndromic ASD.
Moreover, a complete screening for all of the IMD is not feasible
in a standard hospital setting [20]. Targeted testing could more
effectively identify IMD that require early treatment. Plasma and
urine amino acid profiles allow the detection of PKU and HCY,
while urinary organic acid profiles can identify all of the organic
acidurias, some of which include autistic signs [21,22]. In creatine
deficiency syndromes, autistic features are mostly not isolated but
associated with ID, speech delay and epilepsy [23,24]. A few
inborn errors of purine (especially adenylosuccinase deficiency)
and pyrimidine (especially dihydropyrimidine dehydrogenase
deficiency) metabolism [25] may include autism in association
with psychomotor retardation, epilepsy and muscular wasting in
adenylosuccinase deficiency [26].
The two abnormalities identified in our cohort are remarkable.
The patient with persistent creatine urinary excretion may have
had a mild and so far uncharacterized creatine transporter defect.
Moreover, on brain magnetic resonance spectroscopy imaging, the
patient had a low but discernible creatine peak whereas in creatine
transport defects, the creatine peak is usually markedly decreased
[27]. Normality of creatine uptake as well as SLC6A8 investigations
were not in favor of a primary disorder of creatine transport. Low
creatine peak on brain spectroscopy has been reported in other
neurogenetic disorders especially in abnormalities of white matter
homeostasis [28]. Elevated creatine urinary excretion in the
patient is most probably a false positive result that might be related
to excessive creatine dietary intake (mainly due to high protein
intake) as previously reported [29]. Unfortunately, we were unable
to call the patient back for diet control. Three-methylglutaconic
aciduria is a non-specific abnormality underlying a highly
heterogeneous and poorly defined group of diseases named the
3-methylglutaconic acidurias [22]. Besides the 3-methylglutaconyl-
CoA hydratase deficiency, an inborn error of leucine catabolism,
the whole group of 3-methylglutagonic acidurias is most probably
seen in the context of various mitochondrial dysfunctions [22].
Further analyses in this direction are underway in this patient.
Notably, a recent study pointed out that mitochondrial
dysfunction may be involved in ASD [30]. In this report, plasma
lactate determination was performed in a restricted sample of 69
patients with ASD. Twenty per cent of them displayed
hyperlactatemia and 7% fulfilled the criteria for a disorder of
oxidative phosphorylation (OXPHOS) [30]. This initial study has
limitations as the autistic clinical phenotype was not well defined.
More recently, a retrospective study of 25 patients with a primary
diagnosis of nonsyndromic autism who were further determined to
have enzyme- or mutation- defined OXPHOS deficiency showed
that 96% of these patients actually exhibited clinical symptoms
differentiating them from idiopathic autism [31]. These results
suggest that careful clinical and biochemical reappraisal is
warranted in patients with ASD initially considered as nonsyn-
dromic, but also confirm that ASD patients with OXPHOS
dysfunction often exhibit other symptoms such as microcephaly,
marked motor delay, sensorineural deafness, oculomotor abnor-
malities, exercise intolerance, cardiomyopathy or renal tubular
dysfunction. Accordingly, we decided not to screen for hyperlac-
tatemia in our nonsyndromic ASD population. Furthermore,
normal plasma lactic acid concentrations do not exclude the
presence of a mitochondrial disorder [32,33]. Recent reports
emphasize a putative association between mitochondrial dysfunc-
tion and autism (for review see [34]) and highlight the role of brain
energy metabolism dysfunction as an important target for future
studies [35]. In ASD, as already emphasized for several
neurodegenerative disorders [36,37,38,39], mitochondrial dys-
function could be regarded as a secondary defect in brain energy
metabolism.
With the metabolic workup conducted in the sample of 274
patients diagnosed with nonsyndromic ASD, we were unable to
detect any of the screened IMD in any of our patients but one,
who exhibited persistent urinary excretion of 3-methylglutaconic
acid. Our data showed negative results in 99.5% of cases, which
did not differ from the estimated prevalence of IMD in the general
population [40]. Moreover, the causative relationship between the
unspecific 3-methylglutaconic aciduria and ASD is unclear and
remains to be proven. These results strongly call into question the
utility of a systematic metabolic workup in these patients. Few
studies have previously explored the prevalence of IMD associated
with ASD. All of them have been performed on restricted cohorts
of ASD patients. One study reported that none of the 53 patients
with ASD, screened for ammonia, amino acids, lactic acid and
pyruvic acid in blood and urinary organic acids, exhibited
abnormal results [41]. Also, Wang et al. compared the urinary
creatine and guanidinoacetate to creatinine ratios between 57
ASD patients and 49 unrelated control samples. They did not
detect any significant difference between groups suggesting that
creatine deficiency syndromes are not more frequent in patients
with ASD than in controls [42].
Several limitations of this study should be underlined. First, we
considered as nonsyndromic ASD patients with ID. We assumed
that altered mechanisms in the central nervous system in ASD
could involve a wide variety of clinical diagnoses crossing
categorical boundaries, specifically ID [3]. At the opposite, some
authors consider that the co-occurring ASD in association with ID
Autism and Metabolic Diseases
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suggested that ASD patients with ID should be regarded as
syndromic ASD [43]. Second, the retrospective study design is a
limiting factor. Finally, the failure to detect any IMD in our group
of patients might be due to the limited sample size; much larger
study groups would be warranted to detect extremely rare IMD.
Conclusions and Perspectives
The data reported here strongly support the view already
stressed by others [20,44] that systematic metabolic investigations
are not contributive to the etiology of nonsyndromic ASD. On the
other hand, early diagnosis and proper therapeutic intervention
for some metabolic disorders causing nonsyndromic ASD may
significantly improve the long-term cognitive and behavioral
outcomes [20]. Therefore, a careful clinical evaluation, with
cautious reappraisal of clinical signs, is crucial. Such a medical
practice appears more reasonable than a costly systematic workup.
Finally, a large population based prospective study assessing the
benefits of routine metabolic screening in nonsyndromic ASD
would be of great interest in the future to confirm our results.
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